12. April 2021 | Corporate News

Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms

Press release

The full press release is available as download here:

Last Patient Completes Marinomed Biotech AG’s Phase II Clinical Trial of Tacrosolv to Treat Ocular Hay Fever Symptoms
(131 KB)